Biogen (BIIB)/Forward Pharma (FWP) on Watch Amid Oral Interference/IPR Hearings

November 30, 2016 1:22 PM EST

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Biogen (NASDAQ: BIIB) and Forward Pharma (NASDAQ: FWP) could be volatile as the USPTO interference and IPR oral hearing is today. The trial could potentially have a significant impact on Biogen's Tecfidera.

Shares of BIIB are down 1.8% currently and FWP is flat and hasn't traded.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk

Add Your Comment